Details for Patent: 7,297,346

Which drugs does patent 7,297,346 protect, and when does it expire?

Patent 7,297,346 protects NUVIGIL and PROVIGIL and is included in two NDAs.

Protection for NUVIGIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-two patent family members in twenty-eight countries.

Summary for Patent: 7,297,346

Title:	Pharmaceutical formulations of modafinil
Abstract:	The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.
Inventor(s):	Corvari; Vincent (Carmel, IN), Grandolfi; George (Millford, OH), Parikh; Alpa (Hockessin, DE)
Assignee:	Cephalon Inc. (Frazer, PA)
Application Number:	10/155,913
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 7,297,346

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cephalon	NUVIGIL	armodafinil	TABLET;ORAL	021875-001	Jun 15, 2007	AB	RX	Yes	No
Cephalon	NUVIGIL	armodafinil	TABLET;ORAL	021875-002	Mar 26, 2009		DISCN	Yes	No
Cephalon	NUVIGIL	armodafinil	TABLET;ORAL	021875-003	Jun 15, 2007	AB	RX	Yes	No
Cephalon	NUVIGIL	armodafinil	TABLET;ORAL	021875-005	Mar 26, 2009	AB	RX	Yes	No
Cephalon	NUVIGIL	armodafinil	TABLET;ORAL	021875-004	Jun 15, 2007	AB	RX	Yes	Yes

International Family Members for US Patent 7,297,346

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	033910
Argentina	041242
Austria	357228
Austria	434435
Australia	2002318155